此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

心力衰竭风险导向筛查试点研究 - 先导研究 (FIND HF)

2026年9月30日 更新者:Prof Christopher Gale、University of Leeds

FIND HF:心力衰竭的风险导向筛查

The goal of this clinical trial is to learn if the FIND HF algorithm detection rates of heart failure during testing are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk in a population identified as at risk of undiagnosed heart failure. The main questions it aims to answer are:

  • Are people who are identified as high risk by the FIND-HF tool more likely to be diagnosed with heart problems during testing than those identified as low risk?
  • Are people identified as high risk by the FIND-HF tool more likely to show signs of heart problems during testing than those identified as low risk?? Researchers will compare patients in the high risk and low risk groups to see if more patients are detected with asymptomatic heart failure in the high risk group compared to the low risk group.

Participants will attend one visit at a local clinic where they will undergo an NT proBNP blood test which indicates heart failure and an echocardiogram to evaluate the heart's chambers, valves and overall function to help diagnose various heart conditions.

研究概览

地位

邀请报名

条件

详细说明

Background Heart failure (HF) affects around 1-2% of adults globally and is a leading cause of unplanned hospital admissions, especially among older people. In the UK alone, over one million people have HF, with about 200,000 new cases each year. This increase is mainly due to an aging population and better survival rates following heart attacks.

From the perspective of treatment, there are three main categories of HF:

  • HF with reduced ejection fraction (HFrEF)
  • HF with mid-range ejection fraction (HFmrEF)
  • HF with preserved ejection fraction (HFpEF) For HFrEF, four pillar therapy (diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, lanoxin) is established as the gold standard for pharmacotherapeutic management, helping to reduce the risk of death and hospital admissions. For HFpEF and HFmrEF, medications like empagliflozin, dapagliflozin, and finerenone have shown promising results in reducing risks. New drugs like Semaglutide and Tirzepatide are also beneficial for HFpEF patients with obesity. There are now more treatment options for HF than ever before.

In the UK, nurse-led teams in the community are capable of initiating and adjusting HF treatments. However, diagnosing HF early, before severe symptoms appear, remains challenging. Current guidelines recommend specific tests for diagnosis, but many (8 out of 10) diagnoses are still made in hospitals, often late.

The NHS aims to improve early diagnosis in primary care to reduce hospital admissions and improve patients' quality of life.

Funded by the British Heart Foundation (BHF) the investigators have developed an AI algorithm, FIND-HF, to identify people at risk of undiagnosed HF using data from routinely collected electronic health records.

Aims of the project The research project aims to determine the effectiveness of the FIND-HF AI algorithm in identifying HF at different risk levels and to understand the potential benefits of early detection and treatment.

The investigators will quantify the burden of symptoms, natriuretic peptide levels, and diagnostic yield of asymptomatic left ventricular systolic dysfunction, HFrEF, HFmrEF, and HFpEF at different FIND-HF AI risk scores. Using this information, the investigators will establish the risk score threshold that would be used for a future randomised clinical trial (RCT) of early detection of HF.

In addition, amongst patients newly diagnosed with HF during the study, the investigators seek to quantify the pharmacological treatment opportunities to inform the potential effect size, and thus sample size, of a future RCT of early detection and treatment of HF to reduce heart failure hospitalisation and cardiovascular death.

Identification of participants and recruitment Participants will be identified through by having their HF risk estimated their primary care electronic health records.

Individuals will be divided into two categories based on the predicted HF risk with recruitment 1:2 guided by risk strata, with 151 participants in the top 10 percentiles of risk, and 302 participants from the bottom 90 percentiles. This approach aims to enrich the cohort with higher risk patients while also including lower risk patients to determine whether there is an increase in the yield of new HF diagnosis from across the range of FIND-HF AI risk estimates.

Study invitations will be sent to eligible participants in each risk category in batches until the target sample size is reached. The invitation process will consist of a text message followed by an information pack in the post including a participant information sheet, consent form, contact information form and freepost return envelope. Participants will return the consent form and contact information to the research team who will then contact them to make an appointment for the study visit. The study visit will take place at the participant's GP surgery or a community-based health hub.

All participants will be required to provide written informed consent. Study visit

Consenting participants will attend one study visit. During the visit, a British Society of Echocardiography (BSE)-accredited clinical member of the research team will carry out the following tests/investigations:

  • Medical history and symptom assessment (breathlessness, orthopnea, paroxysmal nocturnal dyspnea, exercise intolerance, fatigue, ankle swelling)
  • Height, Weight, HR and BP
  • Natriuretic peptide testing: Participants will undergo point of care (POC) natriuretic peptide testing
  • Echocardiography: Participants will receive an AI-enabled hand-held echocardiogram using the Kosmos device and US2.ai automated measurements.

New cases of HF will be reported to the participant and their GP. Their GP will have responsibility to refer the participant as per local protocol.

Follow up Participants will be followed up remotely through their primary care EHRs at 6 months, and 1-, 5- and 10-years from their study visit by a member of the research team. Follow-up will include assessment of HF therapy and HF events. Consent will be sought for linkage to secondary care records, death certificate data and national registries.

Expected value of results The NHS Major Conditions Strategy stresses the need for evolving care models to better serve the public, with a focus on early diagnosis of cardiovascular disease using AI and digital technology. This proof-of-concept study will inform the design of a trial to test AI risk stratification and community-based pathways for early diagnosis and treatment of heart failure (HF), aiming to reduce HF events and cardiovascular death. If successful, the AI model (FIND-HF) could be implemented across UK primary care for a community-based early HF diagnostic pathway in the NHS.

研究类型

观察性的

注册 (估计的)

475

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • West Yorkshire
      • Leeds、West Yorkshire、英国、LS2 9JT
        • University of Leeds

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients identified at risk of developing Heart Failure by the FIND HF algorithm and are aged 40 and over, living in the Yorkshire area.

描述

Inclusion Criteria:

Registered with a doctor practice that uses electronic health system to record patient medical notes Age at enrolment greater or equal to 40 Identified as at risk of developing Heart Failure

Exclusion Criteria:

Registered with a doctor practice that is participating in research studies relating to heart failure screening

  • Known diagnosis of HF
  • On the palliative care register
  • Unable to give written informed consent for participation in the study
  • Unable to adhere to the study requirements

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Patients at risk of developing Heart Failure

Patients will attend one visit with a Cardiology specialist Clinical research fellow who will carry out tests to detect Heart Failure

Algorithm developed by the research team to identify patients at risk of heart failure that is currently undetected.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To determine whether detection rates of a composite of asymptomatic LVSD, HFrEF, HFmREF, or HFpEF during diagnostics are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk
大体时间:Through study completion, an average of 12 months from date of enrolment

Odds ratio of asymptomatic LVSD, HFrEF, HFmREF, or HFpEF detection rates from intervention in people identified as high HF risk compared with people identified as low HF risk

Through study completion, an average of 12 months from date of enrolment

次要结果测量

结果测量
措施说明
大体时间
To determine if components of composite outcome during diagnostics are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk
大体时间:Through study completion, an average of 12 months from date of enrolment

Odds ratio for each component of the composite in in people identified as high HF risk compared with people identified as low HF risk

Through study completion, an average of 12 months from date of enrolment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Chris P. Gale, Yes、University of Leeds

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月24日

初级完成 (估计的)

2027年7月1日

研究完成 (估计的)

2028年10月1日

研究注册日期

首次提交

2025年9月30日

首先提交符合 QC 标准的

2026年1月19日

首次发布 (实际的)

2026年1月26日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • FIND HF Pilot study
  • PG.25.12417 (其他赠款/资助编号:British Heart Foundation)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Planning to commercialise algorithm

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅